Recruiting soon

GLP-1 SupplemeL-Arginine Supplement for Appetite and GLP-1 in Overweight Adults

What is being tested

High Dose Supplement

+ Low Dose Supplement

+ Placebo

Dietary Supplement

Who is being recruted

From 18 to 60 Years

See all eligibility criteria

How is the trial designed

Prevention Study

Placebo-Controlled

Interventional

Study Start: January 2025

See protocol details

Summary

Principal SponsorTexas Christian University

Study ContactElisa Marroquin, PhDMore contacts

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: January 15, 2025

Actual date on which the first participant was enrolled.

This study explores how a dietary supplement containing L-arginine, resveratrol, tart cherry, and vitamin C affects hunger and the release of a hormone called GLP-1 in people who are overweight or have obesity. GLP-1 is important for controlling appetite and blood sugar levels. The ingredients in the supplement are thought to work together to help people feel full and improve metabolic health. This research could lead to better ways to manage weight and enhance the health of individuals with obesity or metabolic issues. Participants in this study will try different doses of the supplement and a placebo in a random order. Before each session, they will fast for eight hours, then receive the supplement or placebo. After a short rest, they will eat a standardized meal, and their hunger levels and blood samples will be collected at several points. This helps researchers measure changes in hunger and other metabolic markers like glucose and insulin levels. The main risks include minor issues from blood draws and possible discomfort from the supplement, but these are managed with professional care and safety measures. The study aims to see if the supplement can effectively reduce hunger and improve metabolic indicators compared to a placebo.

Official TitleAcute Effect of Supplement Containing L-Arginine on Appetite Suppression and GLP-1 Induction

NCT06790771

Principal SponsorTexas Christian University

Study ContactElisa Marroquin, PhDMore contacts

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

25 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

Inclusion Criteria: Participants must meet all the following conditions to be eligible for the study: * Age: 18-60 years old. * BMI (Body Mass Index): Between 25 and 40 kg/m². * Diet and Activity Stability: Willing to maintain current dietary and physical activity habits for the duration of the study. Exclusion Criteria: Participants will be excluded from the study if any of the following conditions apply: * Recent Weight Change: Lost or gained more than 5% of body weight in the last 3 months. * Pregnancy or Lactation: Pregnant or breastfeeding women. * Medical Conditions: * Kidney disease (Chronic Kidney Disease or End-Stage Renal Disease). * Herpes simplex. * Uncontrolled diabetes (HbA1c \>7%). * Thyroid disorders or taking thyroid medications. * Type 1 diabetes. * Cushing syndrome. * Cirrhosis or hepatitis. * Chronic obstructive pulmonary disease (COPD). * Dementias. * Active autoimmune diseases (e.g., lupus, rheumatoid arthritis). * Crohn's disease or ulcerative colitis. * Celiac disease. * Allergies or Sensitivities: * Known allergies to any components of the supplement or standardized meal. * Medications: Currently taking any of the following: * Supplements or medications for weight loss. * Antihypertensive, antidiabetic, or antihyperlipidemic medications. * Erectile dysfunction medications. * Blood thinners (e.g., aspirin, warfarin). * Medications containing nitric oxide or nitroglycerin. * Drugs affecting GLP-1 levels, such as GLP-1 receptor agonists, insulin, certain antidepressants, or corticosteroids. * Substance Use: Evidence of illegal drug use, including marijuana. * Participation in Other Studies: Enrollment in another clinical trial that could interfere with the study outcomes.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

3 intervention groups are designated in this study

33.333% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental

In the high-dose supplement arm, participants consume approximately 10 grams of the nutritional supplement, which contains 9,000 mg of L-arginine, 200 mg of resveratrol, 500 mg of tart cherry, and 100 mg of vitamin C. After an 8-hour fasting period, participants visit the lab, where a baseline blood sample is collected before supplement consumption. They then rest for 60 minutes to allow absorption and subsequently eat a standardized meal (Bertolli Chicken Alfredo pasta bake) ad libitum within 30 minutes. Blood samples are collected at eight time points, and hunger levels are measured using a 7-point satiety scale. This arm is expected to show the most pronounced effects on GLP-1 secretion and hunger suppression compared to the other arms, highlighting the potential efficacy of a high-dose intervention.

Group II

Experimental

In the low-dose supplement arm, participants consume approximately 5 grams of the supplement, consisting of 4,500 mg of L-arginine, 100 mg of resveratrol, 250 mg of tart cherry, and 50 mg of vitamin C. As in the high-dose arm, participants arrive after fasting for 8 hours, provide a baseline blood sample, and consume the supplement before a 60-minute rest. Following the rest period, they eat the same standardized meal ad libitum within a time window of 30 minutes. Blood samples are again taken at eight time points, and hunger levels are recorded using the same scale. This arm evaluates whether a reduced dose of the supplement provides moderate effects on GLP-1 secretion and hunger suppression, potentially identifying a lower effective dose.

Group III

Placebo

The placebo arm serves as the control condition, using a \~5 g powder with no active ingredients. Participants follow the same protocol as the other arms, including an 8-hour fasting period, baseline blood sample collection, and consumption of the placebo before a 60-minute rest. They then eat the standardized meal ad libitum (within a time window of 30 minutes), with blood samples collected at the eight time points and hunger levels assessed using the 7-point scale. The placebo arm is expected to show minimal or no effect on GLP-1 secretion and hunger suppression, providing a baseline for comparison against the two active supplement doses.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Texas Christian University

Fort Worth, United StatesOpen Texas Christian University in Google Maps

Recruiting soonOne Study Center